.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Johnson and Johnson
Cipla
Boehringer Ingelheim
Medtronic
Moodys
Citi
Cerilliant
McKesson
Harvard Business School

Generated: November 24, 2017

DrugPatentWatch Database Preview

Abarelix - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for abarelix and what is the scope of abarelix freedom to operate?

Abarelix
is the generic ingredient in one branded drug marketed by Speciality European and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Abarelix has sixty-one patent family members in thirty-four countries and five supplementary protection certificates in five countries.

Summary for abarelix

US Patents:3
Tradenames:1
Applicants:1
NDAs:1
Bulk Api Vendors: 16
Clinical Trials: 2
Patent Applications: 6,335
Drug Prices:see low prices
DailyMed Link:abarelix at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Speciality European
PLENAXIS
abarelix
INJECTABLE;INTRAMUSCULAR021320-001Nov 25, 2003DISCNNoNo► Subscribe► SubscribeY ► Subscribe
Speciality European
PLENAXIS
abarelix
INJECTABLE;INTRAMUSCULAR021320-001Nov 25, 2003DISCNNoNo► Subscribe► SubscribeY ► Subscribe
Speciality European
PLENAXIS
abarelix
INJECTABLE;INTRAMUSCULAR021320-001Nov 25, 2003DISCNNoNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: abarelix

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Speciality European
PLENAXIS
abarelix
INJECTABLE;INTRAMUSCULAR021320-001Nov 25, 2003► Subscribe► Subscribe
Speciality European
PLENAXIS
abarelix
INJECTABLE;INTRAMUSCULAR021320-001Nov 25, 2003► Subscribe► Subscribe
Speciality European
PLENAXIS
abarelix
INJECTABLE;INTRAMUSCULAR021320-001Nov 25, 2003► Subscribe► Subscribe
Speciality European
PLENAXIS
abarelix
INJECTABLE;INTRAMUSCULAR021320-001Nov 25, 2003► Subscribe► Subscribe
Speciality European
PLENAXIS
abarelix
INJECTABLE;INTRAMUSCULAR021320-001Nov 25, 2003► Subscribe► Subscribe
Speciality European
PLENAXIS
abarelix
INJECTABLE;INTRAMUSCULAR021320-001Nov 25, 2003► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: abarelix

Country Document Number Estimated Expiration
Czech Republic9902066► Subscribe
Japan2000508345► Subscribe
Israel130309► Subscribe
Spain2299192► Subscribe
Colombia4910114► Subscribe
Russian Federation2202371► Subscribe
Poland334076► Subscribe
Poland199121► Subscribe
CroatiaP970674► Subscribe
New Zealand579443► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ABARELIX

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90014-9Sweden► SubscribePRODUCT NAME: ABARELIX
2011 00004Denmark► SubscribePRODUCT NAME: ABARELIX, EVENTUELT I FORM AF ET FARMACEUTISK SALT; NAT. REG. NO/DATE: 44637 (DK) 20100827; FIRST REG. NO/DATE: DE 578900000 20050922
C0015France► SubscribePRODUCT NAME: ABARELIX, EVENTUELLEMENT SOUS FORME DE SEL PHARMACEUTIQUEMENT ACCEPTABLE; REGISTRATION NO/DATE IN FRANCE: 69026150 DU 20101126; REGISTRATION NO/DATE AT EEC: 57890.00.00 DU 20050922
C/GB11/006United Kingdom► SubscribePRODUCT NAME: ABARELIX, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: DE - 20050922; UK PL32828/001 20100917
00484Netherlands► SubscribePRODUCT NAME: ABARELIX, EVENTUEEL IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; NAT. REGISTRATION NO/DATE: RVG 104389 20101220; FIRST REGISTRATION: 57890.00.00 20050922
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
US Army
Cerilliant
Teva
Merck
Daiichi Sankyo
Healthtrust
Covington
Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot